When was Spark Therapeutics founded?

Spark Therapeutics was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Spark Therapeutics located?

Spark Therapeutics is headquartered in Philadelphia, United States.

Who is the current CEO of Spark Therapeutics?

Jeffrey Marrazzo of Spark Therapeutics.

How many employees does Spark Therapeutics have?

As of Mar 31, 2026, the latest employee count at Spark Therapeutics is 304.

Is Spark Therapeutics a funded company?

Spark Therapeutics is a funded company, having raised a total of $82.8M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 22, 2013.

How much is Spark Therapeutics worth?

The last known valuation of Spark Therapeutics was $***** as of Feb 22, 2019.

When was the latest funding round of Spark Therapeutics?

Spark Therapeutics' latest funding was a $***** Series B round on May 23, 2014, with participation from 6 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $711M in funding in 2026 to date.

What is the annual revenue of Spark Therapeutics?

Annual revenue of Spark Therapeutics is between $50M and $100M as on Dec 31, 2018

Where does Spark Therapeutics rank among its competitors?

Spark Therapeutics ranks 5th amongst 799 active competitors, of which 265 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Spark Therapeutics?

Spark Therapeutics' top competitors include BridgeBio, Alnylam and Alexion. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Spark Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Spark Therapeutics an acquired company?

Spark Therapeutics got acquired by Roche on Feb 22, 2019.

Company Details

Developer of gene therapy for rare diseases. It offers engineered adeno associated viruses to deliver the target gene sequence to the patient for RPE-65 mediated inherited retinal dystrophies. The company is also developing therapies for choroideremia, hemophilia A&B, and neurodegenerative diseases such as Batten's disease.

Website: sparktx.com
Social

Key Metrics

Founded Year

2013

Location

Philadelphia, United States

Stage

Acquired

Total Funding

$82.8M in 2 rounds

Latest Funding Round

Series B, May 23, 2014, $*****

Last Known Valuation

$***** as on Feb 22, 2019

Investors

Sofinnova Investments & 7 more

Ranked

5^th among 799 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2018

Employee Count

304 as on Mar 31, 2026

Investment & Acquisitions

CombiGene & 1 more

Similar Companies

BridgeBio & 982 more

Exit Details

Acquired by Roche (Feb 22, 2019)

View Spark Therapeutics' full profile

Spark Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Spark Therapeutics, Inc. CIN: 1609351 , United States, Active	Mar 12, 2013	$50M - $100M (As on Dec 31, 2018)	822 (As on Dec 31, 2021)	-

Spark Therapeutics got acquired by Roche on Feb 22, 2019 at an acquisition amount of $*****.

Click here to take a look at Spark Therapeutics's acquisition in detail

Spark Therapeutics has raised a total funding of $82.8M over 2 rounds. Its first funding round was on Oct 22, 2013. Its latest funding round was a Series B round on May 23, 2014 for $*****. 6 investors participated in its latest round. Spark Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of Spark Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 23, 2014	6124148	Series B	4990762	7102188	9776145	3177811
Oct 22, 2013	3834323	Series A	6807807	1806879	5880051	Children's Hospital of Philadelphia

Access funding benchmarks and valuations. Sign up today!

View details of Spark Therapeutics's funding rounds and investors

The founders of Spark Therapeutics are Katherine High and Jeffrey Marrazzo.

Here are the details of Spark Therapeutics' key team members:

Katherine High: Co-Founder & CSO, MD of Spark Therapeutics. They are also an angel investor in 1 startup.
Jeffrey Marrazzo: Co-Founder & CEO of Spark Therapeutics.

View details of Spark Therapeutics's Founder profiles and Board Members

Spark Therapeutics' employee count trend

Spark Therapeutics has 304 employees as of Mar 26. Here is Spark Therapeutics's employee count trend over the years:

Employee count trend for Spark Therapeutics

Uncover Spark Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Spark Therapeutics include BridgeBio, Alnylam and Alexion. Here is the list of Top 10 competitors of Spark Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Brookside Capital, T. Rowe Price & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
9th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Xontogeny & 7 others	70/100
10th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100